Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Bought by Vontobel Holding Ltd.

Vontobel Holding Ltd. increased its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 32.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,940 shares of the biotechnology company’s stock after acquiring an additional 4,647 shares during the period. Vontobel Holding Ltd.’s holdings in Iovance Biotherapeutics were worth $178,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. ORG Partners LLC acquired a new position in shares of Iovance Biotherapeutics in the 2nd quarter valued at $32,000. Quest Partners LLC raised its position in shares of Iovance Biotherapeutics by 1,237.7% in the 2nd quarter. Quest Partners LLC now owns 5,003 shares of the biotechnology company’s stock worth $40,000 after buying an additional 4,629 shares during the period. Fidelis Capital Partners LLC acquired a new position in Iovance Biotherapeutics in the first quarter valued at $87,000. EverSource Wealth Advisors LLC purchased a new stake in Iovance Biotherapeutics during the second quarter valued at about $58,000. Finally, Daiwa Securities Group Inc. increased its stake in Iovance Biotherapeutics by 754.0% during the second quarter. Daiwa Securities Group Inc. now owns 8,813 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 7,781 shares during the last quarter. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on IOVA shares. StockNews.com upgraded Iovance Biotherapeutics to a “sell” rating in a report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Monday, August 12th. Finally, Piper Sandler lowered shares of Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $19.00 to $10.00 in a research report on Monday, July 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.00.

Iovance Biotherapeutics Price Performance

Shares of IOVA stock opened at $9.82 on Thursday. The company’s fifty day moving average price is $10.25 and its two-hundred day moving average price is $9.90. The firm has a market capitalization of $2.75 billion, a P/E ratio of -5.46 and a beta of 0.62. Iovance Biotherapeutics, Inc. has a 12 month low of $3.47 and a 12 month high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.01. Iovance Biotherapeutics had a negative return on equity of 65.04% and a negative net margin of 1,343.27%. The business had revenue of $31.11 million for the quarter, compared to analysts’ expectations of $24.59 million. During the same quarter in the previous year, the firm posted ($0.47) earnings per share. The company’s revenue was up 12969.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Iovance Biotherapeutics, Inc. will post -1.26 EPS for the current year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.